All In Biotech

Drug Trial Radar · NCT02960594

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

Last checked: Nov 19, 2026Latest source record: Nov 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Dec 2014

Primary completion

Nov 9, 2018

Study completion Nov 9, 2018

Sponsor

Lead sponsor
Inovio PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
University of Pennsylvania; University of North Carolina; Thomas Jefferson University; University of Pittsburgh; Barbara Ann Karmanos Cancer Institute; Mayo Clinic
First posted
Nov 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.

Conditions

  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • ColoRectal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • HepatoCellular Carcinoma

Interventions

  • INO-1400Biological

  • INO-9012Biological

  • INO-1401Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events graded in accordance with "Common Terminology Criteria for Adverse Events (CTCAE)", NCI version 4.03Time frame: Up to 2 years from first study treatment
  2. Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration siteTime frame: Up to 14 weeks
  3. Changes in safety laboratory parametersTime frame: Up to 2 years from first study treatment

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • University of North Carolina

    Chapel Hill, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.